Project Grant 2031727

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective July 1, 2025, through June 30, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project focused on developing Stable Prophylactic Antibodies (SPABs) that maintain efficacy over extended periods. The primary deliverable is the creation of enhanced antibody mutations that significantly...

Federal Project Grant Summary Piezo Therapeutics, Inc. received a $304,742 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to develop a novel intradermal delivery platform for nucleic acid vaccines. The company will design and optimize a handheld electroporation pen device that delivers naked nucleic acid vaccines directly to immune cells without requiring lipid nanoparticles...

This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...

Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...

The National Science Foundation Division of Industrial Innovation awarded MBF Therapeutics Inc. a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) from January 1, 2022 to December 31, 2022. The grant funds the development of a protective T cell vaccine for SARS CoV-2 (COVID-19). The Engineering program supports innovation, creativity and excellence in engineering research and education to improve quality of life and economic strength. This award furthers those...

Tempo Therapeutics, Inc. received a $1 million cooperative agreement from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a multivalent vaccine platform to provide durable immunity against multiple coronaviruses. Specifically, the funding will support Tempo Therapeutics' efforts to determine the optimal dose, assess durability of immune response, evaluate protective immunity against SARS-CoV-2 variants, and develop a...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $256,000 will develop Recombinant BCG as a novel immunoadjuvant for viral infections. The awardee, Oncosting LLC located in Baltimore, Maryland, will optimize media and lyophilization manufacturing of BCG-STING, evaluate its immunological effects as an adjuvant for H1N1 influenza vaccination, and assess its protective effects as an H1N1 vaccine adjuvant. By adding stimulator of...

Pumpkinseed Technologies Inc. received a $353,204 Phase I Small Business Innovation Research (SBIR) Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on June 19, 2025, with completion targeted for April 30, 2026. The award funds development and proof-of-concept demonstration of Cell-MAPP (Cell Monitoring Against Presented Peptides), a novel technology that enables dynamic, real-time monitoring of individual T cell states during antigen...